RARA CRAFT DATABASE for FDA Medical Devices
510(k)K182703

FDA DEVICE FACTS

EntericBio Dx Assay

Serosep , Ltd.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJune 19, 2019PRODUCT CODEPCH

Indications for use

The EntericBio® Dx assay, performed on ABI 7500 Fast Dx real- time instrument, is an in vitro multiplexed nucleic acid test for the direct, simultaneous, qualitative detection and identification of multiple enteric pathogens in Cary -Blair preserved stool specimens from individuals with signs and symptoms of infectious colitis or gastroenteritis. The test is based on detection of nucleic acids from:

• Salmonella enterica spp.

• Shigella spp./ Enteroinvasive E. coli (EIEC)

• Campylobacter spp. (jejuni, coli and lari)

• STEC (Shiga-like toxin-producing E. coli), stx1/stx2 genes

• Vibrio spp. (cholerae and parahaemolyticus)

• Giardia lamblia (also known as G. intestinalis and G. duodenalis)

• Entamoeba histolytica

Testing is performed on Cary-Blair preserved diarrheal specimens from symptomatic patients with suspected acute gastroenteritis, enteritis or colitis of bacterial or parasitic origin. The test is performed directly on the specimen, utilizing real-time polymerase chain reaction (PCR) for the amplification of Salmonella -specific, Campylobacter -specific, Shigella/ EIEC -specific ipaH, stx1/stx2, Vibrio-specific, Entamoeba-specific and Giardia-specific gene sequences. The test utilizes fluorogenic sequence -specific hybridization probes for the detection of the amplified DNA.

This test is intended for use, in conjunction with clinical presentation, laboratory findings and epidemiological information, as an aid in the diagnosis of Salmonella, Shigella / EIEC , Shiga-like toxin-producing E. coli, Campylobacter spp., Vibrio spp., Entamoeba histolytica and Giardia spp. infections in humans.

Results of this test should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Positive results do not rule out co -infection with other organisms that are not detected by this test and may not be the sole or definitive cause of patient illness. Negative EntericBio® Dx assay results in the setting of clinical illness compatible with gastroenteritis may be due to infection by pathogens that are not detected by this test or non -infectious causes such as ulcerative colitis, irritable bowel syndrome, or Crohn’s disease.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 25, 2026